[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-centrifugal-cicatricial-alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-centrifugal-cicatricial-alopecia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,61,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100632038","phase-2-deucravacitinib-in-the-treatment-of-cicatricial-alopecias-100632038",false,"NCT07508488","Deucravacitinib in the Treatment of Cicatricial Alopecias","Inclusion Criteria:\n\n* Participants of any gender, age 18 years or older, at the time of informed consent at Screening\n* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.\n* Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and\u002For CHLG ≥3.\n* Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP (all female participants, regardless of whether or not they have experienced\u002Freported menarche, are considered WOCBP unless they are permanently sterile or confirmed infertile). A WOCBP who is sexually active must use a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, during the intervention period and for at least 28 days after the last dose of study intervention. And if a WOCBP, must have a negative highly sensitive serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline performed before the first dose of study intervention.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Participant's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.\n* Participant has a history of CA for \\> 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.\n* Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).\n* Participant is pregnant or breastfeeding.\n* Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and\u002For during study participation (de novo patients only).\n* Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).\n* Any Psychiatric condition in the opinion of the investigator precludes participation in the study.\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with STUDY PROCEDURES.\n* History of thromboembolic events including DVT and PE or history of inherited coagulopathies.\n* Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n* History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.\n* Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Day 0. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.\n* Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n* Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening.\n* Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, as determined by the PI.\n* Have an active history of alcohol or substance abuse within 1 year prior to Day 0.\n* Participant has received a live attenuated vaccine ≤ 6 weeks prior to study screening.\n* History of adverse systemic or allergic reactions to components of study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.\n* Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.\n* Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1\u002FTYK2 product) within 4 weeks prior to the baseline visit.\n* Any previous use of a TYK2 inhibitor.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus or cyclosporine within 1 week before the baseline visit.\n* Participant has been previously treated with biological drugs in the last 12 weeks for other indications.\n* Participants previously tested with a positive or indeterminable PPD or QFT result, including participants that completed standard tuberculosis therapy.","ALL","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline\u002FDay 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.",[25,26],"Central Centrifugal Cicatricial Alopecia","Frontal Fibrosing Alopecia","RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-10","ACTUAL",{"date":33,"type":31},"2026-05-28",{"date":35,"type":19},"2028-09-30",{"name":37,"class":38},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100630459","phase-2-safety-and-biomarker-responses-of-delgocitinib-jak123tyk2-inhibitor-in-central-centrifugal-cicatricial-alopecia-and-lichen-planopilaris-100630459","NCT07487948","Safety and Biomarker Responses of Delgocitinib (JAK1,2,3\u002FTYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris","A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3\u002FTYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris","Inclusion Criteria:\n\n* Participants of any gender, age 18 years or older, at the time of informed consent at Screening.\n* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.\n* Participant self-reports a history of at least 6 months of CA (LPP or CCCA). Diagnosis will be made clinically (according to the LPPAI10, and\u002For CHLG11) and\u002For histopathologically.\n* Participants who are females of childbearing potential must have a negative urine pregnancy test at screening and must be practicing an adequate and medically acceptable method of birth control for at least 30 days prior to Day 0 and at least 28 days after the last dose of study drug. Acceptable methods of birth control include intrauterine device (IUD) oral, transdermal, implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); tubal ligation; abstinence; barrier methods with spermicide. If not of child-bearing potential, Participants must have a sterile or vasectomized partner; have had a hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in a menopausal state for at least a year.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Participants of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.\n* Participant has a history of CA for ≥ 4 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.\n* Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening.\n* Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).\n* Participant is pregnant or breastfeeding.\n* Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and\u002For during study participation (de novo patients only).\n* Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).\n* Any Psychiatric condition in the opinion of the investigator precludes participation in the study.\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with STUDY PROCEDURES.\n* History of thromboembolic events including DVT and PE or history of inherited coagulopathies.\n* Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.\n* Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Baseline.\n* Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n* Have an active history of alcohol or substance abuse within 1 year prior to Day 0.\n* Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, at determined by the PI.\n* History of adverse systemic or allergic reactions to components of study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.\n* Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.\n* Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1\u002FTYK2 product) within 4 weeks prior to the baseline visit.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus or cyclosporine within 1 week before the baseline visit.\n* Participant has been previously treated with biological drugs in the last 12 weeks for other indications.",{"count":48,"type":19},30,[22],"This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).",[25,52],"Lichen Planopilaris","2026-06-02",{"date":55,"type":31},"2026-06-04",{"date":57,"type":31},"2026-05-19",{"date":59,"type":19},"2027-12-31",{"name":37,"class":38},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":68,"minAge":16,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":20,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":39},"100421173","a-pilot-study-of-revian-red-all-led-cap-as-a-novel-treatment-for-central-centrifugal-cicatricial-alopecia-100421173","NCT04764331","A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia","A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia.","Inclusion Criteria:\n\n* Women who are eighteen years of age or older with a biopsy-proven diagnosis of CCCA Stage II-III. They also must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and\u002For post 8 rounds of intralesional steroids) for at least 3 months.\n* Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.\n\nExclusion Criteria\n\n* Subjects with other forms of hair loss that is not CCCA\n* Prior treatment with light source for alopecia\n* Males are excluded from this study since the prevalence of CCCA in males is so significantly low that it is difficult to find cases in a clinical setting","FEMALE","75 Years",{"count":71,"type":19},5,[73],"NA","Central centrifugal cicatricial alopecia (CCCA) is form of scarring hair loss that predominately affects middle-aged women of African descent.1 . Clinically, the natural progression of CCCA starts at the crown as roughly circular scarred patches, which evolve into scarred areas increasing in size circumferentially. Characteristically, the scar is often smooth and shiny, and the hair density in the affected area is frequently decreased. The hair remaining in the scarred areas is more brittle and shorter than the hair in unaffected areas. Since CCCA is a scarring disorder, it can cause permanent hair loss, dyesthesias, and psychological distress which can affect overall quality of life. Affected individuals may complain of pruritus, pain, or tenderness.2\n\nThe management of CCCA is challenging due to limited current treatments and a lack of randomized controlled trails. Management focuses on behavioral and styling modifications, in addition to symptomatic relief. Any potentially damaging hair care practices such as chemical relaxers, heat application to the scalp, and the use of hardening gels and sprays are discouraged.3 Many commonly used therapies are anti-inflammatory in nature, including intralesional steroids, topical steroids, oral antibiotics and increased frequency of hair washing with antidandruff shampoos.4 These treatments not only lead to improvement in pruritus and tenderness, but in some cases result in increased hair density.5 Since there is limited investigation done to determine the most effective treatment approach for CCCA subjects, it would be of great benefit to determine if there is any advantage in using one particular anti-inflammatory therapy over others and whether one is more efficacious in relieving symptoms or promoting hair regrowth in follicles that have not yet become scarred.\n\nThe Revian Red All LED cap is a dual-band LED light therapy wireless \"smart\" cap. It has been effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women. There are also reportedly minimal side effects, unlike with topical minoxidil which can cause pruritus and initial hair shedding in the first few weeks, or finasteride which can cause gynecomastia and loss of libido. In this study we hope to see if the anti-inflammatory capabilities of this cap can improve scalp symptoms, reduce hair loss, and promote maturation of vellus and intermediate hairs in non-scarred areas of the scalp in those affected by CCCA.",[25],"2026-03-03",{"date":78,"type":31},"2026-03-04",{"date":80,"type":31},"2021-07-06",{"date":82,"type":19},"2026-11",{"name":84,"class":38},"Wake Forest University Health Sciences",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":68,"minAge":16,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":20,"phases":94,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":39},"100592822","phase-4-effect-of-platelet-rich-plasma-versus-placebo-in-the-treatment-of-central-centrifugal-cicatricial-alopecia-100592822","NCT06998433","Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia","Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Female\n* Minimum age of 18 years old\n* Self-identification as person of African descent, including African, Afro-Caribbean, Afro-Latino, and\u002For African American\n* Clinical diagnosis of mild to moderate CCCA located on the vertex or fronto-vertex scalp, and as defined by Central Hair Loss Grade stages 1B, 2B, and 3B\n\nExclusion Criteria:\n\n* Intralesional or systemic anti-inflammatory medications (corticosteroids, tetracycline antibiotics, anti-malarials) or immunosuppressive drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, janus kinase inhibitors) within 4 weeks of baseline visit\n* Pregnant women\n* Topical minoxidil, metformin, or retinoic acid for 4 weeks prior to baseline visit\n* Severe or end-stage CCCA, Central Hair Loss Grade stage \\>3B\n* Thrombocytopenia (as defined by baseline platelet count \\< 150,000 platelets per microliter of blood)\n* Antiplatelet or platelet altering medications (such as but not limited to aspirin, NSAIDS, clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole) within 4 weeks of baseline visit\n* Diagnosis of other significant concomitant alopecia\n* Clinically significant uncontrolled disease, malignancy, or major psychiatric illness requiring hospitalization (as determined by investigator)\n* Subjects not willing to follow suggested hair care practices such as limiting\u002Favoiding traction-associated styles",{"count":93,"type":19},56,[95],"PHASE4","This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of African descent. CCCA is a condition that leads to permanent hair loss, usually starting at the top of the scalp and spreading outward. It can also cause discomfort, such as itching, burning, and pain.\n\nThe goal is to see if PRP, which comes from the patient's own blood and is thought to reduce inflammation and promote healing, can stop hair loss and even encourage hair regrowth. PRP has been used to treat other types of hair loss, but it has not been widely studied for CCCA.\n\nParticipants in the study will be women of African descent who have been diagnosed with mild to moderate CCCA. Some participants will receive PRP injections, while others will receive a placebo (an inactive treatment) as part of a randomized, double-blind trial. All participants will continue using a topical steroid treatment, which is the standard of care for this condition.\n\nThe study will also look at growth factors in participants' blood to understand how they may affect hair loss or regrowth. The goal is to gather information that could lead to better treatments for CCCA, a condition that currently has no standard treatment guidelines.\n\nAlthough there are risks such as minor discomfort from blood draws and scalp injections and\u002For a small risk of disease progression, the potential benefits include improved hair growth and a better understanding of CCCA treatments.",[25],[99,100,101,102,103,104],"CCCA","scarring alopecia","alopecia","hair loss","PRP","platelet rich plasma","NOT_YET_RECRUITING","2025-09-19",{"date":108,"type":31},"2025-09-24",{"date":110,"type":19},"2025-09-30",{"date":112,"type":19},"2026-07-31",{"name":114,"class":38},"Baylor College of Medicine"]